Info/Contact for David Akin

Get On The Hill updates in your RSS reader

David Akin's Facebook profile

Search this blog:
Custom Search
Subscribe to this blog using your favourite feed reader:
Login
User name:
Password:
Remember me 

Who pays for this blog?
I receive no fees, considerations, etc. etc. for the posts on this blog nor do I have any plans to accept any. My salary is paid by Canwest Global Communications Corp. I work for that company as the Ottawa-based National Affairs Correspondent for Canwest News Service.
The blog publishing platform used here is called Blogware and it's developed by Tucows Inc. of Toronto, Ontario, Canada. My use of Blogware should not be taken as an endorsement of that company. Like all Blogware users, I do not pay any fees for the use of this service.
I participate in program. Google pays me some money and, for that, I give Google some space on this site to display ads. Google sells those ads and Google, not me, decides what advertising content you are seeing. I do not filter these ads and take no responsibility for them. Readers should not assume I endorse any of the products or services advertised here.
If you think other disclosures are appropriate in this space, I'd like to hear from you. All of my contact details are always at
www.davidakin.com You can read more about this section



View Article  Cost of developing new drugs: $1 billion plus ...

All of this was germane to the government because the lobby group for the big pharmaceuticals had been pushing for an extension on their patent protections, promising, in return, to spend 10 per cent of Canadian sales on R&D in Canada. The Industry Canada policy officers note that: "... after peaking in 1997 at 12.9% [of sales], [Big Pharma spending on R&D] has declined to 8.5% in 2006. The dollar value of their R&D has been flat at about $1.2 billion while sales have continued to grow. However, it is important to note that this percentage does not include the S1.5 billion of biotechnology R&D in Canada undertaken by companies who do not yet have a patented product on the market."

   more »
View Article  Copyright, fair dealing, satire and parody: Some background

One of the issues that politicians will grapple with, as they balance the rights of content creators against those of content users is the concept of fair dealing when it comes to satire and parody. The Copyright Act says exempts research or private study, criticism or review, news reporting as "fair dealing" but does not specifically say you can use copyrighted content in satire or parody.I recently received a document, retrieved under Canada's Access to Information laws, that looks at that issue. The document is a briefing note, prepared by Associate Deputy Minister Paul Booth (last seen leading the auto restructuring file for the federal government) for then-Minister Jim Prentice. It's two pages long but here's an even briefer summary...

   more »

Top Stories
This Month
July 2009
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31
Year Archive